November 29, 2023

Patient-Reported Outcomes Improved With Myectomy for Obstructive HCM

But improvements didn’t correlate closely with physician-assigned NYHA class, study finds

23-HVI-4317308_septal-myectomy_650x450

Patient-reported outcomes (PROs) are significantly improved after septal myectomy for obstructive hypertrophic cardiomyopathy (oHCM), but they do not necessarily correlate closely with physician-reported New York Heart Association (NYHA) class. So finds an analysis by Cleveland Clinic researchers of follow-up data from symptomatic patients in the SPIRIT-HCM study.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“At 12-month follow-up in symptomatic oHCM patients, septal myectomy significantly improved patient-reported outcomes, left ventricular outflow tract (LVOT) obstruction and functional capacity,” says senior author Milind Desai, MD, MBA, Director of Cleveland Clinic’s Hypertrophic Cardiomyopathy Center. “However, the results also underscore the discrepancy between what patients report about their quality of life, in terms of patient-reported outcome measures, and how physicians perceive their symptoms.”

The new analysis, published in Progress in Cardiovascular Diseases (2023;80:66-73), adds to a previous report of results from the single-center SPIRIT-HCM trial (JAMA Netw Open. 2022;5[4]:e227293), which showed that in patients with oHCM, septal myectomy significantly improves Kansas City Cardiomyopathy Questionnaire (KCCQ) scores for quality of life (QOL) as well as physical and health status.

Study essentials

The investigator-initiated, single-arm SPIRIT-HCM study prospectively enrolled 173 symptomatic adults aged 18 to 65 with oHCM who were undergoing surgical septal myectomy at Cleveland Clinic; all were in NYHA class II or III/IV at baseline. Three outcomes were assessed in the new analysis: the association between various PROs, their association with NYHA class and changes after septal myectomy.

Historically, observational studies of septal myectomy for HCM have used NYHA class to measure outcomes. “Quality-of-life assessment with patient-reported outcomes increasingly is being accepted as a more reliable outcome metric, and one better aligned with patient perception of physical and mental function,” Dr. Desai notes.

The PROs used to assess patients at baseline and 12 months post-procedure were KCCQ scores, the Patient-Reported Outcomes Measurement Information System (PROMIS), the Duke Activity Status Index (DASI) and the European QOL score (EQ-5D). None of those instruments were specifically designed to assess QOL in patients undergoing interventions for oHCM.

NYHA class, results of a 6-minute walk test (6MWT) and peak LVOT gradient also were recorded at baseline and 12 months.

Advertisement

At baseline, 35% to 49% of patients in NYHA class II had PRO scores worse than the cohort median, whereas 30% to 39% of patients in NYHA class III//IV had PRO scores better than median.

“This cohort had a median baseline KCCQ summary score that was worse than has previously been reported in oHCM studies, which suggests our patients were a sicker population and had substantially impaired quality of life,” observes study co-author Maran Thamilarasan, MD, staff cardiologist in Cleveland Clinic’s Section of Cardiovascular Imaging.

High consistency among PROs

At 12 months after surgery, the authors found the following:

  • 80% of the patients had a ≥20-point improvement in KCCQ summary score
  • 83% had a ≥4-point improvement in DASI score
  • 86% had a ≥4-point improvement in PROMIS physical score
  • 85% had a ≥0.04-point improvement in the EQ-5D

Notably, there was a highly statistically significant internal consistency among the various PROs, both at baseline and following myectomy. The magnitude of benefit of the procedure on the individual PROs also was very high.

Less correlation between PROs and other measures

In contrast, post-surgery improvements were more modest in physician-assessed NYHA class, with only 67% of patients assigned to class I at 12 months, and in peak LVOT gradient and 6MWT. Both at baseline and during follow-up, there was substanial overlap of PRO results within various NYHA classes.

“Our findings demonstrate that patients’ perceptions of their symptoms, physical and mental function, and quality of life cannot necessarily be ascertained from objective measures such as exercise stress testing,” says study co-author Nicholas Smedira, MD, MBA, Surgical Director of Cleveland Clinic’s Hypertrophic Cardiomyopathy Center. “This underscores the importance of directly assessing patient-reported outcomes.”

Advertisement

He adds that the study findings did not surprise him: “Post-myectomy, many patients send me cards and letters saying they cannot remember feeling so well, that they can run and hike and play with their children again without getting short of breath or lightheaded. It is truly life-changing for patients.”

Future research opportunities

The researchers noted that 6MWT results and PROMIS mental domain scores did not improve in a significant proportion of patients after myectomy. On follow-up, only 44% of patients increased their 6MWT result beyond 100 meters. Factors that the authors believe may be contributory ― and that they intend to investigate in future studies ― include diastolic dysfunction, overzealous beta blockade, obesity and deconditioning associated with long-term physical activity restriction prior to surgery.

Other areas for exploration include better defining the heterogeneity of the benefits of myectomy by examining which social, demographic, clinical and physiologic parameters are most strongly associated with improved status (or lack thereof) in patients with oHCM.

“In future trials, patient-reported outcomes, rather than NYHA class, should be emphasized as inclusion criteria and/or endpoints for judging success,” says Dr. Desai. “In addition, the patient-reported outcomes we assessed can be used to guide clinical management and make decisions about drug titration or recommendations for invasive therapies.”

Related Articles

23-HVI-4475649 CQD 650×450
January 24, 2024
Low Mortality Is Possible in Elective Multivalve Cardiac Reoperations

Volume-based experience and judicious patient selection are central to success

23-HVI-4453014 CQD 650x450a
January 12, 2024
Introducing Our Newest Cardiothoracic Surgeons

Four recent hires add bench strength and diversity to meet complex patient needs

illustrations of chambers of the human heart
December 18, 2023
Outcomes of Mitral Valve Re-Repair for Early Recurrent Posterior Leaflet Prolapse

Cleveland Clinic series shows re-repair is feasible with excellent midterm results

23-HVI-3868208-cardiac-surgery-650×450
June 21, 2023
Surgeon and Institutional Experience Drive Reduced Mortality After Cardiac Reoperations

Intentional culture of safety extends outcome gains to both novice and late-career surgeons

implanted bioprosthesis for aortic valve replacement
May 9, 2023
Is It Time to Redefine ‘Low Risk’ Surgical Aortic Valve Replacement?

Cleveland Clinic study finds expected STS risk no longer reflects current outcomes

22-HVI-3450158_coronary-revascularization_650x450
February 1, 2023
The Case Against Downgrading CABG Recommendations for Patients With Severe Three-Vessel Disease

Weakened endorsements in settings of normal EF and mild-moderate LV dysfunction may cause harm

22-HVI-3361352_staged-thoracoabdominal-aortic-aneurysm-repair_650x450
November 25, 2022
Ultra-Hybrid Repair of Thoracoabdominal Aortic Aneurysm: A Good Option for Pan-Aorta Involvement

Large series finds outcomes from staged “endo-open” strategy comparable to open repair

Ad